| 1.97 0.1 (5.35%) | 02-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.39 |
1-year : | 2.79 |
| Resists | First : | 2.04 |
Second : | 2.39 |
| Pivot price | 1.92 |
|||
| Supports | First : | 1.88 |
Second : | 1.78 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 1.91 |
| MA(100) : | 1.95 |
MA(250) : | 1.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 22.6 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 2.54 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MNOV ] has closed below upper band by 32.9%. Bollinger Bands are 45.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.04 - 2.05 | 2.05 - 2.06 |
| Low: | 1.85 - 1.86 | 1.86 - 1.87 |
| Close: | 1.96 - 1.97 | 1.97 - 1.98 |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Thu, 13 Feb 2025
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
Tue, 11 Feb 2025
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Mon, 03 Feb 2025
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
Sun, 26 Jan 2025
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - MarketBeat
Thu, 05 Dec 2024
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
Tue, 19 Nov 2024
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 21.2 (%) |
| Shares Short | 182 (K) |
| Shares Short P.Month | 197 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | -982 % |
| Return on Assets (ttm) | -9.6 % |
| Return on Equity (ttm) | -13.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -9.39 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 96.62 |
| Price to Cash Flow | -11.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|